Cardot E, Tillie-Leblond I, Jeannin P, Facon A, Breuil K, Patte F, Tonnel A B
Service de Pneumologie et Immunoallergologie, Hôpital A. Calmette, Centre Hospitalier Regional et Universitaire, Lille.
J Allergy Clin Immunol. 1995 Jan;95(1 Pt 1):1-7. doi: 10.1016/s0091-6749(95)70145-1.
Systemic reactions during anesthesia are commonly attributed to muscle relaxants, hypnotics, macromolecular solutions, latex, or parenteral antibiotics. After exclusion of these different components as causes, we were interested in the potential implication of rifamycin in the systemic reaction, which occurred during anesthesia, and in the immunologic mechanism by which it can trigger this reaction.
We report four cases of systemic reactions occurring after local administration of rifamycin. Three patients needed orthopedic surgery, and the fourth needed a urethrotomy. Severe systemic reactions occurred in all four patients when the surgeon washed the incision area with a rifamycin solution. All patients correctly responded to appropriate treatment and recovered. Skin tests were performed 2 months after the incident with the drugs used during anesthesia, latex, and rifamycin. To assess the relationship with a possible IgE-mediated mechanism, two in vitro tests were concomitantly performed to evaluate the cell reactivity to rifamycin: (1) determination of histamine release from peripheral basophils and (2) platelet cytotoxicity test, which explored the presence on platelets of specific IgE antibodies bound to the low-affinity receptor for IgE.
Skin tests were performed with different drugs used during surgery, and results were only positive for rifamycin in the four cases, accompanied in two cases by a systemic reaction. Histamine release from basophils was positive in three of four patients. The platelet cytotoxicity test results were positive in all four cases.
It appears that rifamycin, used locally during surgery, is apt to trigger severe systemic anaphylactic reactions, which are linked to an IgE-related process. This situation is worth pointing out, especially in patients who undergo repeated orthopedic operations during which, at least in Europe, rifamycin is commonly used for the prevention of local sepsis.
麻醉期间的全身反应通常归因于肌肉松弛剂、催眠药、大分子溶液、乳胶或胃肠外抗生素。在排除这些不同成分作为病因后,我们关注利福霉素在麻醉期间发生的全身反应中的潜在影响,以及它引发这种反应的免疫机制。
我们报告了4例局部应用利福霉素后发生全身反应的病例。3例患者需要进行骨科手术,第4例需要进行尿道切开术。当外科医生用利福霉素溶液冲洗切口区域时,所有4例患者均发生了严重的全身反应。所有患者对适当的治疗均有正确反应并康复。事件发生2个月后,对麻醉期间使用的药物、乳胶和利福霉素进行了皮肤试验。为了评估与可能的IgE介导机制的关系,同时进行了两项体外试验以评估细胞对利福霉素的反应性:(1)测定外周嗜碱性粒细胞组胺释放;(2)血小板细胞毒性试验,该试验探讨血小板上与IgE低亲和力受体结合的特异性IgE抗体的存在情况。
对手术期间使用的不同药物进行了皮肤试验,4例病例中仅利福霉素试验结果为阳性,其中2例伴有全身反应。4例患者中有3例嗜碱性粒细胞组胺释放试验结果为阳性。4例病例的血小板细胞毒性试验结果均为阳性。
手术期间局部使用的利福霉素似乎易于引发严重的全身过敏反应,这与IgE相关过程有关。这种情况值得指出,尤其是在接受重复骨科手术的患者中,至少在欧洲,利福霉素通常用于预防局部感染。